Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

1. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a
hierarchy that originates from a primitive hematopoietic cell. Nature
1997;3(7):730–737.
2. Al–Hajj M, Wicha MS, Benito–Hernandez A, et al. Prospective identification
of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A
2003;100(7):3983–3988.
3. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain
tumour initiating cells. Nature 2004;432:396–401.
4. O’Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell
capable of initiating tumour growth in immunodeficient mice. Nature
2007;445:106–110.
5. Ricci–Vitiani L, Lombardi DG, Pilozzi E, et al. Identification
and expansion of human colon cancer-initiating cells. Nature
2007;445:111–115.
6. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization
of human colorectal cancer stem cells. Proc Natl Acad Sci U S A
2007;104(24):10158–10163.
7. Hamburger A, Salmon SE. Primary bioassay of human tumor stem
cells. Science 1977;197(4302):461–463.
8. Hamburger A, Salmon SE. Primary bioassay of human myeloma stem
cells. J Clin Invest 1977;60(4):846–854.
9. Aye MT, Niho Y, Till JE, et al. Studies of leukemic cell populations in
culture. Blood 1974;44(2):205–219.
10. Brunschwig A, Southam CM, Levin AG. Host resistance to cancer.
Clinical experiments by homotransplants, autotransplants, and admixture
of autologous leucocytes. Ann Surg 1965;162(3):416–425.
11. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating
human melanomas. Nature 2008;451(7176):345–349.
12. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer
stem cells. Nature 2001;414(6859):105–111.
13. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance
by preferential activation of the DNA damage response. Nature
2006;444(7120):756–760.
14. Hirschmann–Jax C, Foster AE, Wulf GG, et al. A distinct “side population”
of cells with high drug efflux capacity in human tumor cells. Proc
Natl Acad Sci U S A 2004;101(39):14228–14233.
15. Tumbar T, Guasch G, Greco V, et al. Defining the epithelial stem cell
niche in skin. Science 2004;303(5656):359–363.
16. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer
stem cells. Nature 2001;414(6859):105–111.
17. Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of
cancer-stem-cell research. Nat Rev Cancer 2005;5(4):311–321.
18. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct “side population”
of cells with high drug efflux capacity in human tumor cells. Proc
Natl Acad Sci U S A 2004;28;101(39):14228–14233.
19. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct “side population”
of cells in human tumor cells: implications for tumor biology and
therapy. Cell Cycle 2005;4(2):203–205.
20. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem
cell in human brain tumors. Cancer Res 2003;63:5821–5828.
21. Ponti D, Costa A, Zaffaroni N, et al. Isolation and in vitro propagation
of tumorigenic breast cancer cells with stem/progenitor cell properties.
Cancer Res 2005;65(13):5506–5511.
22. Yu F, Yao H, Zhu P, et al. let-7 regulates self renewal and tumorigenicity
of breast cancer cells. Cell 2007;131:1109–1123.
23. Fang D, Nguyen TK, Leishear K, et al. A tumorigenic subpopulation
with stem cell properties in melanomas. Cancer Res 2005;65(20):
9328–9337.
24. Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed
progenitor to leukaemia stem cell initiated by MLL-AF9. Nature
2006;442(7104):818–822.
25. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors
as candidate leukemic stem cells in blast-crisis CML. N Engl J
Med 2004;351(7):657–667.
26. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell
biology to cancer. Nat Rev Cancer 2003;3:895–902.
27. Lobo NA, Shimono Y, Qian D, et al. The biology of cancer stem cells.
Annu Rev Cell Dev Biol 2007;23:675–99.
28. SR. ACS. Age-Adjusted Cancer Death Rates, Females or Males by Site,
US, 1930–2001 US Mortality Public Use Data Tapes 1960–2001, US
Mortality Volumes 1930–1959, National Center for Health Statistics .
Centers for Disease Control and Prevention, 2004.
29. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J
Clin 2007;57(1):43–66.
30. De Petris L, Crino L, Scagliotti GV, et al. Treatment of advanced nonsmall
cell lung cancer. Anna Oncol 2006;17(Suppl 2):II36–II41.
31. Quint LE, Tummala S, Brisson LJ, et al. Distribution of distant metastases
from newly diagnosed non-small cell lung cancer. Ann Thorac Surg
1996;62:246–250.
32. Pisters KM, Ginsberg RJ, Giroux DJ, et al. Induction chemotherapy
before surgery for early-stage lung cancer: a novel approach. Bimodality
Lung Oncology Team. J Thorac Cardiovas Surg 2000;119(3):
429–439
33. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the
epidermal growth factor receptor underlying responsiveness of nonsmall
cell lung cancer to gefitinib. N Engl J Med 2004;350(21):
2129–2139.
34. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer:
correlation with clinical response to gefitinib therapy. Science
2004;304(5676):497–500.
35. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are
common in lung cancers from “never smokers” and are associated with
sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A
2004;101(36):13306–13311.
36. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and
resistance of non-small cell lung cancer to gefitinib. N Engl J Med
2005;352(8):786–792.
37. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas
to gefitinib or erlotinib is associated with a second mutation
in the EGFR kinase domain. PLoS Med 2005;2:E73.
38. Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor
receptor gene mutation in patients with non-small cell lung cancer
and acquired resistance to gefitinib. Clin Cancer Res 2006;12(19):
5764–5769.
39. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance
of non-small-cell lung cancer to gefitinib. N Engl J Med 2005 Feb
24;352(8):786–792.
40. Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF
receptor may circumvent acquired resistance to gefitinib. Proc Natl
Acad Sci U S A 2005;102(21):7665–7670.
41. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung
adenocarcinomas to gefitinib or erlotinib is associated with a second
mutation in the EGFR kinase domain. PLoS Med 2005 Mar;2(3):e73.
42. Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF
receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad
Sci U S A . 2005;102(21):7665–7670.
43. Yun CH, Mengwasser KE, Torns AV, et al. The T790M mutation in
EGFR kinase causes drug resistance by increasing the affinity for ATP.
Proc Natl Acad Sci U S A 2008;105(8):2070–2075.
44. Li D, Shimamura T, Ji H, et al. Bronchial and peripheral murine lung
carcinomas induced by T790M-L858R mutant EGFR respond to HKI-
272 and rapamycin combination therapy. Cancer Cell 2007;12:81–93.
45. Ho MM, Ng AV, Lam S, et al. Side population in human lung cancer
cell lines and tumors is enriched with stem-like cancer cells. Cancer Res
2007;67(10):4827–4833.
46. Eramo A, Lotti F, Sette G, et al. Identification and expansion of
the tumorigenic lung cancer stem cell population. Cell Death Differ
2007;15(3):504–514.
47. Kim CFB, Jackson EL, Woolfenden AE, et al. Identification of bronchioalveolar
stem cells in normal lung and lung cancer. Cell 2005;121:823–835.
48. Gomperts BN, Strieter RM. Stem cells and chronic lung disease. Ann
Rev Med 2007;58:285–298.
49. Giangreco A, Reynolds SD, Stripp BR. Terminal bronchioles harbor a
unique airway stem cell population that localizes to the bronchoalveolar
duct junction. Am J Pathol 2002;161(1):173–182.
50. Ling TY, Kuo MD, Li CL, et al. Identification of pulmonary Oct-
4 stem/progenitor cells and demonstration of their susceptibility to
SARS coronavirus (SARS-CoV) infection in vitro. Proc Natl Acad Sci
U S A 2006;103(25):9530–9535.
51. Schmidt M, Sun G, Stacey MA, et al. Identification of circulating fibrocytes
as precursors of bronchial myofibroblasts in asthma. J Immunol
2003;171(1):380–390.
52. Phillips RJ, Burdick MD, Hong K, et al. Circulating fibrocytes traffic
to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest
2004;114(3):438–446.
53. Parker R, Joseph J, Dussek J, et al. Respiratory system. In: Williams PL,
Bannister LH, Berry MM, et al., eds. Gray’s Anatomy . 38th Ed. New York:
Churchill Livingstone, 1999:1627–1682.
54. Rodenhuis S, Slebos RJ, Boot AJ, et al. Incidence and possible clinical
significance of K-ras oncogene activation in adenocarcinoma of the
human lung. Cancer Res 1988;48(20):5738–5741.
55. Kobayashi T, Tsuda H, Noguchi M, et al. Association of point mutation
in c-Ki-ras oncogene in lung adenocarcinoma with particular
reference to cytologic subtypes. Cancer 1990;66(2):289–294.
56. Mills NE, Fishman CL, Rom WN, et al. Increased prevalence of K-ras
oncogene mutations in lung adenocarcinoma. Cancer Res 1995;55(7):
1444–1447.
57. Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation
and progression using conditional expression of oncogenic K-ras. Genes
Dev 2001;15:3243–3248.
58. Sweet-Cordero A, Mukherjee S, Subramanian A, et al. An oncogenic
KRAS2 expression signature identified by cross-species gene-expression
analysis. Nat Genet 2005;37:48–55.
59. Onn A, Isobe T, Itasaka S, et al. Development of an orthotopic model
to study the biology and therapy of primary human lung cancer in
nude mice. Clin Cancer Res 2003;9(15):5532–5539.
60. Fujino H, Kondo K, Ishikura H, et al. Matrix metalloproteinase inhibitor
MMI-166 inhibits lymphogenous metastasis in an orthotopically implanted
model of lung cancer. Mol Cancer Ther 2005;4(9):1409–1416.
61. Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche
matters. Cancer Res 2006;66(9):4553–4557.
62. Scadden DT. The stem-cell niche as an entity of action. Nature
2006;441:1075–1079.
63. Tumbar T, Guasch G, Greco V, et al. Defining the epithelial stem cell
niche in skin. Science 2004;303:359–363.
64. Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of
cancer-stem-cell research. Nat Rev Cancer 2005;5:311–321.
65. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy
regimens for advanced non-small cell lung cancer. N Engl J
Med 2002;346(2):92–98.
66. Schiller JH, Adak S, Feins RH, et al. Lack of prognostic significance
of p53 and K- ras mutations in primary resected non-small cell lung
cancer on E4592: a laboratory ancillary study on an eastern cooperative
oncology group prospective randomized trial of postoperative adjuvant
therapy. J Clin Oncol 2001;19(2):448–457.
67. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin
vs. observation in resected non-small cell lung cancer. N Engl J Med
2005;352(25):2589–2597.
68. Mucenski ML, Wert SE, Nation JM, et al. -catenin is required for
specification of proximal/distal cell fate during lung morphogenesis.
J Biol Chem 2003;278(41):40231–40238.
69. Shu W, Guttentag S, Wang Z, et al. Wnt/ -catenin signaling acts
upstream of N-myc, BMP4, and FGF signaling to regulate proximaldistal
patterning in the lung. Dev Biol 2005;283(1):226–239.
70. Pongraca JE, Stockley RA. Wnt signaling in lung development and
diseases. Respir Res 2006;7(15).
71. Kotsinas A, Evangelou K, Zacharatos P, et al. Proliferation, but not
apoptosis, is associated with distinct -catenin expression patterns in
non-small cell lung carcinomas. Am J Pathol 2002;161:1619–1634.
72. Ohgaki H, Kros JM, Okamoto Y, et al. APC mutations are infrequent
but present in human lung cancer. Cancer Lett 2004;207(2):197–203.
73. Sunaga N, Kohno T, Kolligs FT, et al. Constitutive activation of the
Wnt signaling pathway by CTNNB1 ( -catenin) mutations in a
subset of human lung adenocarcinoma. Genes Chromosomes Cancer
2001;30(3):316–321.
74. Ueda M, Gemmill RM, West J, et al. Mutations of the - and -
catenin genes are uncommon in human lung, breast, kidney, cervical,
and ovarian carcinomas. Br J Cancer 2001; 85(1):64–68.
75. Mazieres J, He B, You L, et al. Wnt signaling in lung cancer. Cancer
Letters 2005;222:1–10.
76. Pepicelli CV, Lewis PM, McMahon AP. Sonic hedgehog regulates
branching morphogenesis in the mammalian lung. Curr Biol
1998;8(19):1083–1086.
77. Yuan Z, Goetz JA, Singh S, et al. Frequent recombination of hedgehog
signaling in non-small cell lung carcinoma. Oncogene 2007;26:
1046–1055.
78. Vonlanthen S, Heighway J, Altermatt HJ, et al. The bmi-1 oncoprotein is
differentially expressed in non-small cell lung cancer and correlates with
INK4A-ARF locus expression. Br J Cancer 2001;84(10):1372–1376.
79. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies
a death-from-cancer signature predicting therapy failure in patients
with multiple types of cancer. J Clin Invest 2005;115(6):1503–1521.
80. Dovey JS, Zacharek SJ, Kim CF, et al. Bmi1 is critical for lung tumorigenesis
and bronchioalveolar stem cell expansion. Proc Natl Acad Sci
U S A 2008;105(33):11857–11862.
81. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell
2006;127:679–695.
82. Kucia M, Reca R, Miekus K, et al. Trafficking of normal stem cells and
metastasis of cancer stem cells involve similar mechanisms: pivotal role
of the SDF-1-CXCR4 axis. Stem Cells 2005;23:879–894.
83. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of
cancer stem cells determine tumor growth and metastatic activity in
human pancreatic cancer. Cell Stem Cell 2007;1:313–323.
84. Ben–Baruch A. The multifaceted roles of chemokines in malignancy.
Cancer Metastasis Rev 2006;25:357–371.
85. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004;4:
540–550.
86. Su L, Zhang J, Xu H, et al. Differential expression of CXCR4 is associated
with the metastatic potential of human non-small cell lung cancer
cells. Clin Cancer Res 2005;1(11):8273–8280.
87. Takanami I. Overexpression of CCR7 mRNA in non-small cell lung
cancer: correlation with lymph node metastasis. Int J Cancer 2003;
105(2):186–189.
88. Yuan A, Yang PC, Yu CJ, et al. Interleukin-8 messenger ribonucleic
acid expression correlates with tumor progression, tumor angiogenesis,
patient survival, and timing of relapse in non-small cell lung cancer. Am
J Respir Crit Care Med 2000;162(5):1957–1963.
89. McCulloch EA. Stem cells in normal and leukemic hemopoiesis (Henry
Stratton Lecture, 1982). Blood 1983;62(1):1–13.
90. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute
myeloid leukaemia after transplantation into SCID mice. Nature 1994
Feb 17;367(6464):645–648.
91. Dick JE. Normal and leukemic human stem cells assayed in SCID
mice. Semin Immunol 1996;8(4):197–206.
92. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain
tumour initiating cells. Nature 2004 Nov 18;432(7015):396–401.
93. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a
subpopulation of cells with cancer stem cell properties in head and
neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007;104(3):
973–978.
94. Eramo A, Lotti F, Sette G, et al. Identification and expansion of the
tumorigenic lung cancer stem cell population. Cell Death Differ 2008;
15(3):504–514.